Saturday 17 October 2026
Export ANIX’s income statement to Excel — free account
ANIXA BIOSCIENCES INC
ANIX Healthcare Biotechnology
ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00. In the quarter to July 2026, EPS fell 14.3% and free cash flow fell 17.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.67
0.11
−3.96%
Follow ANIX
| Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 | Oct '20 | Oct '19 | Oct '18 | Oct '17 | Oct '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | — | 3 | 3 | 4 | 3 |
P/S ratio |
— | — | 100.72 | — | 190.90 | — | 56.21 | 48.39 | 33.01 | 132.13 |
Altman Z-Score |
— | — | 14.47 | — | 46.96 | — | (14.74) | (9.44) | (9.34) | (32.39) |
Altman Z″-Score (non-manufacturers) |
— | — | (14.64) | — | 9.94 | — | (98.65) | (92.27) | (48.50) | (89.30) |
P/FCF ratio |
— | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (49.72) | — | (139.20) | — | (57.28) | (69.92) | (33.82) | (81.25) |
Beneish M-Score |
— | — | — | — | — | — | (9.37) | — | — | — |
P/B ratio |
— | — | 4.19 | — | 4.18 | — | 15.91 | 13.77 | 3.16 | 57.00 |
Price to Tangible BV |
— | — | 4.20 | — | 4.19 | — | 16.05 | 16.42 | 4.05 | 0.00 |
EV/Sales |
— | — | 80.05 | — | 148.95 | — | 54.68 | 47.51 | 28.94 | 130.19 |
EV/EBITDA |
— | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | (12.53) | — | (22.98) | — | (15.71) | (16.40) | (5.77) | (16.17) |
EV/FCF |
— | — | (12.60) | — | (23.15) | — | (15.13) | (16.25) | (5.80) | (15.50) |
Quick Ratio |
7.71 | 8.04 | 11.89 | 14.60 | 28.13 | 7.62 | 3.99 | 4.24 | 7.69 | 6.91 |
Current Ratio |
8.08 | 8.54 | 12.50 | 14.83 | 28.35 | 7.88 | 4.11 | 4.38 | 7.89 | 7.25 |
Net Debt/EBITDA |
1.29 | 1.44 | 2.17 | 2.15 | 2.73 | 0.92 | 0.51 | 0.36 | 1.20 | 0.89 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.04 | 0.15 | 0.05 | 0.04 |
Operating CF/Net income |
0.66 | 0.58 | 0.63 | 0.48 | 0.38 | 0.62 | 0.41 | 0.31 | 0.54 | 0.67 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.58 | (0.18) | (0.38) | (0.11) | 0.04 | (0.17) |
Interest Coverage |
— | — | — | (133.41) | (5,711.30) | (294.34) | (166.53) | (310.63) | (12.14) | (8.67) |
| (66.55%) | (59.41%) | (38.05%) | (43.18%) | (60.21%) | (153.22%) | (233.04%) | (213.58%) | (157.77%) | (166.85%) | |
| (58.01%) | (53.29%) | (35.08%) | (40.78%) | (56.68%) | (127.24%) | (182.81%) | (183.42%) | (97.20%) | (67.05%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (7,004.46%) | (350.46%) | 0.00% |
Return on Tangible Assets |
(78.50%) | (66.56%) | (42.06%) | (48.27%) | (37.30%) | (122.47%) | (242.02%) | (322.04%) | (113.61%) | (162.44%) |
Average Days of Receivables |
— | 0.00 | 469.29 | 0.00 | 0.00 | 0.00 | 97.09 | 100.72 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 2,270.95% | 0.00% | 1,208.98% | 0.00% | 2,189.36% | 612.40% | 440.72% | 518.83% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,995.71% | 0.00% | 1,381.45% | 0.00% | 2,265.12% | 621.29% | 1,216.74% | 903.27% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.20 | 0.37 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2,254.76% | 0.00% | 1,573.83% | 0.00% | 2,285.48% | 799.60% | 462.57% | 301.63% |
Graham Net Nets |
— | — | 0.24 | — | 0.24 | — | 0.06 | 0.06 | 0.24 | (0.02) |
Graham Number |
— | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (10.13%) | — | (8.64%) | — | (15.25%) | (19.73%) | (30.85%) | (9.13%) |
Free Cash Flow Yield |
— | — | (6.31%) | — | (3.37%) | — | (6.43%) | (6.04%) | (15.13%) | (6.36%) |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.01 | 0.06 | 0.03 | 0.03 |
Operating CF per Share |
(0.22) | (0.23) | (0.20) | (0.21) | (0.17) | (0.28) | (0.24) | (0.24) | (0.31) | (0.39) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | (0.02) |
Free Cash Flow per Share |
(0.22) | (0.23) | (0.20) | (0.21) | (0.17) | (0.28) | (0.25) | (0.24) | (0.31) | (0.40) |
Cash per Share |
0.47 | 0.62 | 0.77 | 0.98 | 1.25 | 0.41 | 0.30 | 0.29 | 0.56 | 0.37 |
Shareholders Equity per Share |
0.43 | 0.59 | 0.75 | 0.93 | 1.22 | 0.37 | 0.24 | 0.29 | 0.65 | 0.11 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.43 | 0.59 | 0.75 | 0.93 | 1.22 | 0.37 | 0.24 | 0.29 | 0.65 | 0.11 |
Free Cash Flow |
(7.17) | (7.33) | (6.21) | (6.49) | (4.90) | (6.19) | (4.92) | (4.31) | (3.78) | (3.53) |
Working Capital |
13.92 | 18.86 | 23.33 | 28.16 | 34.73 | 8.18 | 4.61 | 4.27 | 6.12 | 2.93 |
Capital Expenditures |
— | — | — | — | 0.04 | (0.02) | (0.18) | (0.04) | 0.01 | (0.15) |
Net Current Asset Value |
13.76 | 18.66 | 23.21 | 27.99 | 34.51 | 8.18 | 4.61 | 4.27 | 6.12 | (1.24) |
EV/EBIT |
— | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | — | (0.07) | 0.00 | 0.70 | 0.03 | (0.04) | 0.49 |
Price to Operating Income |
— | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.32 | 4.73 | 6.99 | 5.61 |
Cash ROIC |
(24.63%) | (18.90%) | (13.15%) | (11.21%) | (6.96%) | (35.74%) | (46.15%) | (42.11%) | (25.62%) | (83.49%) |
Accounts Receivable Turnover |
— | 0.00 | 1.33 | 0.00 | 0.00 | 0.00 | 1.34 | 3.15 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.22 | 0.16 | 0.02 | — | 0.03 | 0.19 | 0.35 | — | — |
Average Payables |
0.35 | 0.37 | 0.24 | 0.20 | 0.18 | 0.41 | 0.58 | 0.53 | 0.43 | 0.38 |
Average Assets |
18.84 | 23.56 | 27.97 | 33.33 | 22.86 | 7.87 | 6.37 | 7.63 | 7.22 | 7.48 |
Average Common Equity |
16.42 | 21.13 | 25.79 | 31.48 | 21.52 | 6.54 | 5.00 | 6.55 | 4.45 | 3.01 |
Columns are period end dates